PMID- 10630967
OWN - NLM
STAT- MEDLINE
DCOM- 20000218
LR  - 20221207
IS  - 0146-6615 (Print)
IS  - 0146-6615 (Linking)
VI  - 60
IP  - 3
DP  - 2000 Mar
TI  - HPV16 E6 oncogene variants in women with cervical intraepithelial neoplasia.
PG  - 337-41
AB  - Human papillomaviruses (HPVs) are strongly associated with the development of 
      high grade cervical intraepithelial neoplasia (CIN) and cervical carcinoma, with 
      between 40-80% of patients with cervical carcinoma being attributed to a single 
      HPV type, HPV16 depending on the methods used and geographical location of the 
      particular study [van den Brule et al., 1996]. An HPV16 E6 variant has been 
      described which is strongly associated with high grade CIN [Ellis et al., 1997] 
      and with the human leukocyte antigen (HLA)-B7 genotype in women with cervical 
      carcinoma where HLA-B7 positive patients were demonstrated to have a 
      significantly poorer clinical outcome [Ellis et al., 1995]. To determine whether 
      this HPV16 E6 variant might play a significant role in the pathogenesis of 
      cervical disease, 174 HPV16 positive women were selected from those attending the 
      colposcopy clinics of Guy's and St Thomas' Hospital Trust following polymerase 
      chain reaction (PCR) amplification of HPV16 L1 or E5 DNAs from cervical brush 
      swabs or fixed biopsy tissue. HPV16 E6 DNA was amplified by PCR and the variant 
      sequence was identified by Msp 1 restriction enzyme digestion, as the nucleotide 
      substitution creates an additional unique Msp 1 site. The study group comprised 
      29 normal controls, 7 women with borderline cytology, 123 women with cervical 
      dysplasia and 12 women with cervical cancer. 101/174 (58%) of these women had 
      amplifiable E6 DNA and restriction enzyme digestion was performed on 95 of these. 
      The variant E6 sequence was identified in 3/95 (3%) individuals, two of whom had 
      normal histology and one had a CIN II lesion. Wild type E6 sequence was 
      identified in the remaining 92/95 (97%) individuals. These data suggest that this 
      particular E6 variant does not play a major role in the pathogenesis of HPV16 
      related cervical disease in women living in the South London area.
CI  - Copyright 2000 Wiley-Liss, Inc.
FAU - Luxton, J
AU  - Luxton J
AD  - Peter Gorer Department of Immunobiology, Guy's Hospital, London, United Kingdom.
FAU - Mant, C
AU  - Mant C
FAU - Greenwood, B
AU  - Greenwood B
FAU - Derias, N
AU  - Derias N
FAU - Nath, R
AU  - Nath R
FAU - Shepherd, P
AU  - Shepherd P
FAU - Cason, J
AU  - Cason J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (DNA, Viral)
RN  - 0 (E6 protein, Human papillomavirus type 6)
RN  - 0 (Oncogene Proteins, Viral)
SB  - IM
MH  - DNA, Viral/analysis
MH  - Female
MH  - Genetic Variation
MH  - Humans
MH  - Oncogene Proteins, Viral/*analysis/genetics
MH  - Papillomaviridae/*genetics
MH  - Polymerase Chain Reaction
MH  - Uterine Cervical Dysplasia/*chemistry
EDAT- 2000/01/12 09:00
MHDA- 2000/02/26 09:00
CRDT- 2000/01/12 09:00
PHST- 2000/01/12 09:00 [pubmed]
PHST- 2000/02/26 09:00 [medline]
PHST- 2000/01/12 09:00 [entrez]
AID - 10.1002/(SICI)1096-9071(200003)60:3<337::AID-JMV13>3.0.CO;2-1 [pii]
PST - ppublish
SO  - J Med Virol. 2000 Mar;60(3):337-41.